We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AVID200

News List

Pharmaceutical News of August | PharmaSources.com—Transaction & IPO PharmaSources/Caicai
September 23, 2020
Suzhou Vigonvita Life Sciences completed a new series of equity financing, with Qihoo 360, Share Venture, Ganzhou Qizhi Huikang, and Suzhou Meilingge becoming new shareholders of the company and the registered capital increasing to RMB5,769,231.
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200 americanpharmaceuticalreview
January 10, 2019
Forbius announced the first patient was dosed in a Phase 1 clinical trial with AVID200. The trial will evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects of escalating doses of AVID200 in patients with solid tumors.....